{
    "organizations": [],
    "uuid": "10b239d5ba5b5d8df5ee66e2d04ab8cdb8a5299f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pfenex-announces-top-line-pf708-st/brief-pfenex-announces-top-line-pf708-study-results-in-osteoporosis-patients-idUSFWN1SL14H",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfenex Announces Top-Line PF708 Study Results In Osteoporosis Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 14 (Reuters) - Pfenex Inc:\n* PFENEX ANNOUNCES POSITIVE TOP-LINE PF708 STUDY RESULTS IN OSTEOPOROSIS PATIENTS, ON-TRACK FOR SUBMISSION OF NEW DRUG APPLICATION IN THIRD QUARTER 2018\n* PFENEX INC - ON-TRACK FOR SUBMISSION TO FDA IN Q3 2018, WITH A POTENTIAL COMMERCIAL LAUNCH IN UNITED STATES AS EARLY AS Q3 2019\n* PFENEX INC - NO IMBALANCES IN SEVERITY OR INCIDENCE OF ADVERSE EVENTS FROM PF708 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-15T04:13:00.000+03:00",
    "crawled": "2018-05-15T13:50:49.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "pfenex",
        "inc",
        "pfenex",
        "announces",
        "positive",
        "pf708",
        "study",
        "result",
        "osteoporosis",
        "patient",
        "submission",
        "new",
        "drug",
        "application",
        "third",
        "quarter",
        "pfenex",
        "inc",
        "submission",
        "fda",
        "q3",
        "potential",
        "commercial",
        "launch",
        "united",
        "state",
        "early",
        "q3",
        "pfenex",
        "inc",
        "imbalance",
        "severity",
        "incidence",
        "adverse",
        "event",
        "pf708",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}